Paper Details

  1. Home
  2. Paper Details

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia.

Author: Baccara-DinetMarie T, BanerjeePoulabi, DefescheJoep C, HamonSara C, HopkinsPaul N, KasteleinJohn J P, LangsletGisle, SeizWerner, StefanuttiClaudia

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Alirocumab effectively reduces LDL cholesterol levels in patients with familial hypercholesterolemia, regardless of the specific gene mutation involved in the low-density lipoprotein receptor (LDLR) pathway. This study of 1191 patients found that individuals with a wide spectrum of LDLR, APOB, PCSK9, and other gene mutations experienced similar LDL cholesterol reductions with alirocumab treatment.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Mutation(s) in genes involved in the low-density lipoprotein receptor (LDLR) pathway are typically the underlying cause of familial hypercholesterolemia. OBJECTIVE: The objective of the study was to examine the influence of genotype on treatment responses with alirocumab. METHODS: Pati...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jacl.2017.08.016

データ提供：米国国立医学図書館（NLM）

Alirocumab: A Powerful Oasis in the Desert of Familial Hypercholesterolemia

Familial hypercholesterolemia is a genetic disorder, like a treacherous desert landscape, that can lead to high cholesterol levels. This study investigates the effectiveness of alirocumab, a medication used to lower cholesterol, in patients with familial hypercholesterolemia. The researchers, like skilled explorers, navigated the diverse genetic landscape of familial hypercholesterolemia, studying the impact of different gene mutations on the effectiveness of alirocumab.

A Beacon of Hope for Diverse Genetic Landscapes

The researchers, like meticulous cartographers, mapped the genetic landscape of familial hypercholesterolemia, identifying mutations in a range of genes associated with this disorder. They discovered that alirocumab effectively lowered LDL cholesterol levels, regardless of the specific gene mutation. This research provides valuable insights into the potential of alirocumab as a powerful tool for managing familial hypercholesterolemia, even in the face of diverse genetic landscapes.

A Lifeline for Those with Familial Hypercholesterolemia

This study offers a lifeline for individuals with familial hypercholesterolemia, providing evidence that alirocumab can effectively lower LDL cholesterol levels, regardless of the specific gene mutation. It’s like finding a wellspring of hope in the desert, providing a means for managing this challenging disorder and improving cardiovascular health.

Dr.Camel's Conclusion

This study, like a vibrant oasis in the desert of familial hypercholesterolemia, offers a beacon of hope. By demonstrating the effectiveness of alirocumab across a wide range of gene mutations, the researchers have provided a powerful tool for managing this challenging disorder, improving cardiovascular health and offering a better quality of life for those affected.

Date :
  1. Date Completed 2018-07-09
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

28964736

DOI: Digital Object Identifier

10.1016/j.jacl.2017.08.016

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.